Rich Pharma, a US-based biopharmaceutical company, focuses on developing RP-323, a natural compound that can differentiate cancer cells into normal ones, for the treatment of acute myelogenous leukemia and Hodgkin's lymphoma. RP-323 is being designed to treat blood and cancer-related diseases through non-evasive outpatient facilities, and it can also elevate white blood cells in patients depleted of these elements due to various conditions.